Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/9/2010

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the third quarter ended September 30, 2010.

Regarding the Company's ongoing review of strategic alternatives, Ronald Martell, chief executive officer of Poniard, said: "Poniard is actively focused on the execution of strategic alternatives aimed at optimizing the value of the Company and of our lead program, picoplatin.  This effort is our highest priority, and one for which the management team and its advisors are working diligently to achieve a successful outcome."

Third Quarter 2010 Unaudited Financial ResultsThe Company reported a net loss of $6.4 million ($0.13 diluted loss per share on a loss applicable to common shares of $6.5 million) for the quarter ended September 30, 2010, compared with a net loss of $9.9 million ($0.29 diluted loss per share on a loss applicable to common shares of $10.0 million) for the quarter ended September 30, 2009. For the first nine months of 2010, the net loss was $24.9 million ($0.55 diluted loss per share on a loss applicable to common shares of $25.6 million), compared to a net loss of $32.5 million ($0.95 diluted loss per share on a loss applicable to common shares of $32.9 million) for the same period in 2009.

Total operating expenses for the quarter ended September 30, 2010 were $6.0 million compared with $9.2 million for the quarter ended September 30, 2009. Year to date, total operating expenses were $23.2 million compared to $30.5 million for the first nine months of 2009.

Research and development expenses were $0.9 million for the quarter ended September 30, 2010, compared with $5.1 million for the quarter ended September 30, 2009. Year to date, research and development expenses were $7.9 million, compared to $18.5 million for the same period in 2009.

General and administrative expenses were $5.1 million for the quarter ended September 30, 2010, compared to $4.1 million for the quarter ended September 30, 2009. Year to date, general and administrative expenses were $13.7 million compared to $10.9 million for the same period in 2009. The increase in both periods was primarily attributable to increased accounting and legal fees associated with our evaluation of potential strategic alternatives and to increased share-based compensation for the year to date period.

Cash and investment securities as of September 30, 2010, were $23.3 million, compared to $43.4 million at December 31, 2009. Management currently believes that the existing cash and investment securities will provide adequate resources to fund operations at least through the end of 2010.

Conference Call DetailsPoniard's management team will host a conference call and Webcast today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time. To participate in the call by telephone, please dial 866-804-6921 (United States) or 857-350-1667 (International). The passcode for the conference call is 12705036. In addition, the call is being Webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard PharmaceuticalsPoniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. For additional information please visit http://www.poniard.com.

Forward-Looking StatementsThis release contains forward-looking statements describing, among other things, the Company's projected financial position and future operations, the adequacy of its cash resources, the Company's plan to focus its resources on the continued development of picoplatin, the Company's assessment of the value of the picoplatin asset and the commercial and therapeutic potential of picoplatin, the Company's plan to explore strategic alternatives to support the continued development of picoplatin, and the Company's goal of optimizing shareholder value. Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including the Company's anticipated future operating losses, need for future capital and ability to obtain future funding on a timely basis, on favorable terms, or at all; the risk that strategic relationships may not be established on a timely basis, on terms that are ultimately favorable to the Company, or at all; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's ability to retain key personnel; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of FDA and other required regulatory approvals, if at all; the Company's ability to maintain compliance with Nasdaq listing standards; and other the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.Poniard Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations(In thousands, except per share data)(Unaudited)Three Months Ended September 30,Nine Months Ended September 30,2010200920102009Revenues$
-$
-Operating expenses:Research and development (Note 1)8915,0567,87018,545General and administrative (Note 1)5,0604,14213,74710,929Restructuring & asset impairment--1,6261,056  Total operating expenses5,9519,19823,24330,530Loss from operations(5,951)(9,198)(23,243)(30,530)Other income (expense), net(498)(679)(1,641)(2,017)Net loss(6,449)(9,877)(24,884)(32,547)Preferred stock dividends(48)(125)(688)(375)Loss applicable to common shares$
(6,497)$
(10,002)$
(25,572)$
(32,922)Loss per share:Basic and diluted$
(0.13)$
(0.29)$
(0.55)$
(0.95)Shares used in calculation of loss per share:Basic and diluted48,23734,76946,35734,723Condensed Consolidated Balance Sheets(In thousands)September 30, 2010December 31, 2009(Unaudited)(Note 2)ASSETS:Cash and investment securities$
23,345$
43,389Cash - restricted158281Facilities and equipment, net73219Licensed products, net6,6817,592Other assets887961  Total assets$
31,144$
52,442LIABILITIES AND SHAREHOLDERS' EQUITY:Current liabilities$
2,425$
7,127Long term liabilities6,58511,671Shareholders' equity12,13423,644  Total liabilities and shareholders' equity$
31,144$
52,442Note 1:  Patent related legal expenses are included in G&A expenses. The 2009 expenses have been reclassified above to conform to this presentation.Note 2:  Derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009.
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... -- Clinical Affairs leaders at pharmaceutical organizations are looking to either start ... While some companies have conducted a significant number of clinical trials ... such as India and China ... India are now requiring local clinical trials to ... China and India ...
(Date:2/12/2016)... , Feb. 12, 2016   National Community Pharmacists ... RPh, MBA issued the following statement today in response ... by the Centers for Medicare & Medicaid Services ... NCPA, beneficiary advocates and others: patient advocacy ... are still reviewing the full CMS analysis. Our initial ...
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... ... Series at Zuckerberg San Francisco General Hospital on April 5-7. The series is ... and create new habits. The workshops cover a broad range of topics, including ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... AssureVest Insurance ... areas, is initiating a charity drive that will raise funds earmarked to purchase computers ... C. Tayloe Elementary School. , “My school is in a low-income area and has ...
(Date:2/12/2016)... Pittsburgh, PA (PRWEB) , ... February 12, 2016 ... ... serving families of the Pittsburgh metro area, celebrates the beginning of the latest ... help children develop social skills through art. Donations to this worthy cause are ...
(Date:2/12/2016)... Sugar Land, TX (PRWEB) , ... February 12, ... ... the families of southwest Houston and surrounding communities by continuing it’s commitment to ... Fort Bend Family Promise. The organization works closely with area homeless families to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have a next ... North America’s leading brand of building products, has improved upon its industry-best array ... mobile version of the ColorView® Exterior Style and Color Selector. Created expressly for ...
Breaking Medicine News(10 mins):